Patients in trial to test pioneering cancer treatment by Oxford University

Oxford University

Oxford University

First published in

Cancer patients are to take part in a pioneering research trial run by Oxford University leaders.

One group will take increasing dosages of a new drug CXD101, which is known as a histone deacetylase (HDAC) inhibitor that kills cancer cells by blocking the functions of HDAC enzymes in the body.

The enzymes are needed for cell multiplication, migration and survival so blocking them can stop tumours spreading.

The second will be tested for the HR23B protein that could determine the effectiveness of CXD101 and similar drugs and those with high levels will get the most appropriate dose of CXD101.

The trial is being held with Oxford University Hospitals NHS Trust and 30 to 40 cancer patients. University department of oncology lead researcher Professor Nick La Thangue said: “HDAC inhibitors have had limited success in the past, but CXD101 works in a new way and has great potential to treat many different cancers.”

Related links

Send us your news, pictures and videos

Most read stories

Local Info

Enter your postcode, town or place name

About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree